{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:23:58Z","timestamp":1792693438310,"version":"4.5.0"},"reference-count":44,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2744,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p><jats:bold>Aims\u2002<\/jats:bold> The purpose of this study was to characterize the relationship between the degree of anticoagulation, assessed by APTT, and the plasma concentration of inogatran in healthy subjects and in patients with coronary artery disease.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Data from five phase I studies in 78\u2003healthy males and two phase II multicentre studies in 948 patients of both sexes with unstable angina pectoris or non\u2010Q\u2010wave myocardial infarction were evaluated. A total of 3296 pairs of concentration\u2010APTT samples were obtained before, during, and after intravenous infusions of inogatran. Mixed effects modelling was used for population pharmacodynamic analysis of the drug effect and for describing the variability in baseline APTT.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The population mean baseline APTT was 29\u2003s, but large variations between individuals (s.d. 3.6\u2003s) were observed. The variability between studies (1.3\u2003s) and centres (1.8\u2003s) were of less importance, though statistically significant. APTT increased in a nonlinear manner with increasing inogatran concentration and the relationship was well described by a combined linear and E<jats:sub>max<\/jats:sub> model. A significant part of the overall variability could be ascribed to the APTT reagent and equipment used at the different study centres. These method\u2010dependent differences were compensated for by including the lower limit of the normal reference range as a covariate, affecting both baseline and E<jats:sub>max<\/jats:sub>, in the model. For the typical healthy subject and patient, the method\u2010corrected population mean parameters were: APTT<jats:sub>baseline<\/jats:sub> 35 and 31\u2003s, slope 8.0 and 5.8\u2003s\u2003l\u2003\u00b5mol<jats:sup>\u22121<\/jats:sup>, E<jats:sub>max<\/jats:sub> 36 and 34\u2003s, and E<jats:italic>C<\/jats:italic><jats:sub>50<\/jats:sub> 0.54 and 0.72\u2003\u00b5mol\u2003l<jats:sup>\u22121<\/jats:sup>, respectively. The model predicted plasma concentration needed to double the APTT from the baseline value was 1.25 and 1.45\u2003\u00b5mol\u2003l<jats:sup>\u22121<\/jats:sup> in the healthy volunteer and patient, respectively.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> The nonlinear relationship between APTT and inogatran concentration in plasma was well described by a combined linear and E<jats:sub>max<\/jats:sub> model. Pooling of data was made possible by incorporating a centre\u2010specific characteristic of the assay method in the model. Patients had lower baseline APTT and appeared to have less pronounced effect of inogatran than young healthy subjects.<\/jats:p>","DOI":"10.1046\/j.1365-2125.2001.01326.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:39:57Z","timestamp":1047357597000},"page":"71-79","source":"Crossref","is-referenced-by-count":12,"title":["Population modelling of the effect of inogatran, at thrombin inhibitor, on <i>ex vivo<\/i> coagulation time (APTT) in healthy subjects and patients with coronary artery disease"],"prefix":"10.1111","volume":"51","author":[{"given":"Marie","family":"Cullberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf G.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"71","volume-title":"Hemostasis and Thrombosis: Basic Principles and Clinical Practice","author":"Mann KG","year":"1994"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-3848(96)00230-7"},{"key":"e_1_2_6_4_2","first-page":"211","article-title":"Laboratory assessment of antithrombotic therapy: What tests and if so why?","volume":"27","author":"Kher A","year":"1997","journal-title":"Haemostasis"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.4.1624"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.5.1510"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90187-6"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0038-1651573","article-title":"Anticoagulant activity of HirulogTM, a direct thrombin inhibitor, in humans","volume":"69","author":"Fox I","year":"1993","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.4.1631"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609123351103"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(99)80517-7"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242206"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/107.1.105"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1055\/s-0038-1653754","article-title":"Effects of two different doses of hirudin on APTT, determined with eight different reagents","volume":"73","author":"Monreal M","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(94)90272-0"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/89.1.19"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/ajcp\/110.2.184","article-title":"Monitoring heparin therapy. APTT results from partial\u2010 vs full\u2010draw tubes","volume":"110","author":"Siegel JE","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1055\/s-0038-1649567","article-title":"Effects of hirudin on activated partial thromboplastin time determined with ten different reagents","volume":"70","author":"Tripodi A","year":"1993","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0038-1653728","article-title":"The APTT monitoring of heparin \u2013 the ISTH\/ICSH Collaborative Study","volume":"73","author":"Van der Velde EA","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.5.1568"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-3848(98)00213-8"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.5.2385"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1055\/s-0038-1657729","article-title":"The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis","volume":"78","author":"Elg M","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199601000-00009"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","unstructured":"Teger\u2010NilssonA\u2010C ErikssonU GustafssonD BylundR FagerG&HeldP.Phase I studies on inogatran a new selective thrombin inhibitor.J Am Coll Cardiol Special issue. Abstract from ACC Meeting New Orleans March 1995.1995;117A.","DOI":"10.1016\/0735-1097(95)91943-R"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-199609000-00009"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a015467"},{"key":"e_1_2_6_28_2","unstructured":"NONMEM Users Guides edsBealSL SheinerLB. NONMEM Project Group University of California at San Francisco San Francisco 1992."},{"key":"e_1_2_6_29_2","first-page":"411","volume-title":"The population approach: measuring and managing variability in response concentration and dose","author":"Jonsson EN","year":"1997"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01113502"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061469"},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1001\/archinte.1997.00440420107010","article-title":"Inability of the activated partial thromboplastin time to predict heparin levels: time to reassess guidelines for heparin assays","volume":"157","author":"Baker BA","year":"1997","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1055\/s-0038-1648943","article-title":"Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment","volume":"72","author":"Nurmohamed MT","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1055\/s-0038-1656078","article-title":"Monitoring of r\u2010hirudin anticoagulation during cardiopulmonary bypass \u2013 assessment of the whole blood ecarin clotting time","volume":"77","author":"P\u00f6tzsch B","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_35_2","first-page":"140","article-title":"A recombinant hirudin (IK\u2010HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time","volume":"26","author":"Schenk JF","year":"1996","journal-title":"Haemostasis"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-0038-1650588","article-title":"Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor","volume":"76","author":"Cirillo R","year":"1996","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.04231.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614477"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199309000-00004"},{"key":"e_1_2_6_40_2","first-page":"17","volume-title":"The in vivo study of drug action","author":"Colburn WA","year":"1992"},{"key":"e_1_2_6_41_2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1055\/s-0038-1656077","article-title":"Pharmacodynamic and safety results of PEG\u2010hirudin in healthy volunteers","volume":"77","author":"Esslinger H\u2010U","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_42_2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ajcp\/93.5.684","article-title":"Comparison of two APTT methods of monitoring heparin therapy. APTT ratio and heparin response of pooled normal plasma","volume":"93","author":"Zanke B","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_6_43_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ajcp\/74.5.668","article-title":"Heparin and the activated PTT. A difference between the in vitro and in vivo effects and implications for the therapeutic range","volume":"74","author":"Bain B","year":"1980","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_6_44_2","first-page":"195","volume-title":"Standardization of Coagulation Assays: an Overview","author":"Thomson JM","year":"1982"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050381"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2001.01326.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2001.01326.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.2001.01326.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:29:35Z","timestamp":1697560175000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.2001.01326.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1046\/j.1365-2125.2001.01326.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.2001.01326.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}